# Triamcinolone

## Triamcinolone 10mg/1mL

| 藥物代碼 | ITRI1 |
| :--- | :--- |
| 適應症 | Intra-articular Inflammatory joint disease |
| 副作用 | HPA axis supression, intracranial hypertension, Cushing's syndrome, growth retardation in children; osteoporosis, fractures. Peptic ulceration; glaucoma; hyperglycaemia; GI upsets; increased appetite; increased fragility of skin; behavioural changes. Topical: Systemic absorption if applied to large areas, broken skin or under occlusive dressing. |
| 禁忌 | Untreated systemic fungal, bacterial, viral or parasitic infection, hypersensitivity. Neonates \(Parenteral\) |
| 藥物保存方式 | 室溫 |
| 用法用量 | Intra-articular Inflammatory joint disease As acetonide: Smaller joints: 2.5-5 mg \(up to 10 mg\), larger joints: 5-15 mg \(up to 40 mg\). Max: 20-80 mg/treatment. As hexacetonide: Initial: 2-20 mg/day. |
| 肝功能異常 | 無需調整劑量  需調整劑量 |
| 腎功能異常 | 無需調整劑量  需調整劑量 |
| 懷孕用藥危分級 | 除非治療上需要 |
| 孕期用藥建議 | Human \(and animal\) data suggest risk |
| 附帶說明 | N/A |
| 哺乳期用藥建議 | No \(Limited\) Human Data - Probably Compatible 無\(很少\)資料 - 可使用 |
| 附帶說明 | N/A |
| 注射劑給藥建議途徑 | ID, IM, INS, IVI, SKIN |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | N/A |
| IVP 用法建議 | N/A |
| IVD 用法建議 | N/A |
| 注意事項 | N/A |

## 4% Triamcinolone 40mg/1mL

| 藥物代碼 | ITRI4 |
| :--- | :--- |
| 適應症 | Inflammatory skin conditions. |
| 副作用 | HPA axis supression, intracranial hypertension, Cushing's syndrome, growth retardation in children; osteoporosis, fractures. Peptic ulceration; glaucoma; hyperglycaemia; GI upsets; increased appetite; increased fragility of skin; behavioural changes. Topical: Systemic absorption if applied to large areas, broken skin or under occlusive dressing. |
| 禁忌 | Untreated systemic fungal, bacterial, viral or parasitic infection, hypersensitivity. Neonates \(Parenteral\) |
| 藥物保存方式 | 室溫 |
| 用法用量 | Intradermal Inflammatory skin conditions As acetonide: 1-3 mg/site. Max: 30 mg in total if several sites of inj used. As diacetate: 5 mg in divided doses for small lesions, up to 48 mg in divided doses for large lesions. Max: 12.5 mg/inj site. Max: 25 mg/lesion. As hexacetonide: Max: 80 mcg/cm2 of affected skin. |
| 肝功能異常 | 無需調整劑量  需調整劑量 |
| 腎功能異常 | 無需調整劑量  需調整劑量 |
| 懷孕用藥危分級 | 除非治療上需要 |
| 孕期用藥建議 | Human \(and animal\) data suggest risk |
| 附帶說明 | N/A |
| 哺乳期用藥建議 | No \(Limited\) Human Data - Probably Compatible 無\(很少\)資料 - 可使用 |
| 附帶說明 | N/A |
| 注射劑給藥建議途徑 | ID, IM, INS, IVI, SKIN, SUBCI |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | N/A |
| IVP 用法建議 | N/A |
| IVD 用法建議 | N/A |
| 注意事項 | N/A |

